Close Menu

Strata Oncology

The companies are using Strata's biomarker technology to identify genomic subpopulations of cancer patients who respond to Arcus' investigational immunotherapy drug.

The study is testing the efficacy of cancer treatments that are selected based on genomic markers driving patients' tumors, regardless of cancer type.

Strata will refer individuals with HER-2 mutations identified through its screening trial for consideration as subjects in Puma's SUMMIT trial.

The company intends to use the funds to support submission of its NGS assay to the FDA, adoption of its testing by more health systems, and continued R&D.

The company now partners with 10 healthcare systems to provide free NGS testing to all advanced cancer patients and plans to present patient data this summer.

Get the latest news in the Genetics and Genomics industries right here. For the week of Dec 15, 2017.

The company hopes to build enrollment of men with advanced prostate cancer within its larger Strata Trial — which provides free targeted sequencing and tracks its impact on clinical trial enrollment.

Strata will help Epizyme identify cancer patients for enrollment in a Phase II trial of its non-Hodgkins lymphoma drug tazemetostat.

Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.

The study will provide no-cost tumor sequencing and clinical trial matching to an estimated 100,000 patients with advanced cancers.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.